Amylyx Pharmaceuticals (AMLX) Set to Announce Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) will be posting its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Amylyx Pharmaceuticals to post earnings of $0.24 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03. Amylyx Pharmaceuticals had a return on equity of 12.39% and a net margin of 12.94%. The company had revenue of $108.45 million during the quarter, compared to the consensus estimate of $106.40 million. During the same quarter in the prior year, the firm posted ($0.65) earnings per share. On average, analysts expect Amylyx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Amylyx Pharmaceuticals Price Performance

Amylyx Pharmaceuticals stock opened at $1.97 on Wednesday. The business has a 50 day moving average of $4.81 and a 200-day moving average of $11.51. Amylyx Pharmaceuticals has a 1 year low of $1.70 and a 1 year high of $30.50. The company has a market capitalization of $133.98 million, a P/E ratio of 2.81 and a beta of -0.68.

Insider Transactions at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 1,540 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total transaction of $28,844.20. Following the completion of the sale, the insider now owns 81,372 shares of the company’s stock, valued at approximately $1,524,097.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Gina Mazzariello sold 1,540 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total value of $28,844.20. Following the transaction, the insider now directly owns 81,372 shares in the company, valued at approximately $1,524,097.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Joshua B. Cohen sold 4,135 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total value of $77,448.55. Following the completion of the transaction, the chief executive officer now owns 3,023,002 shares in the company, valued at $56,620,827.46. The disclosure for this sale can be found here. Insiders sold a total of 10,305 shares of company stock valued at $193,098 in the last quarter. 11.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Evercore ISI reaffirmed an “in-line” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. SVB Leerink downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, March 11th. Robert W. Baird downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research report on Monday, March 11th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Amylyx Pharmaceuticals in a research report on Monday, April 8th. Finally, Leerink Partnrs downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, March 11th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $32.67.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.